Century Therapeutics (IPSC) CEO receives major RSU and option grants

Rhea-AI Filing Summary

Century Therapeutics President and CEO Brent Pfeiffenberger received new equity awards. On February 2, 2026, he was granted 475,000 shares of common stock in the form of restricted stock units at a price of $0 per share.

He also received a stock option for 945,000 shares of common stock at an exercise price of $1.84 per share. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting quarterly over three years, while the option vests 25% on February 2, 2027 and the rest in 36 equal monthly installments, all subject to continued service.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Pfeiffenberger Brent

Role President and CEO

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	945,000	$0.00	--
Grant/Award	Common Stock	475,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 945,000 shares (Direct); Common Stock — 3,797,990 shares (Direct)

Footnotes (1)

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock. The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pfeiffenberger Brent

(Last) (First) (Middle)

C/O CENTURY THERAPEUTICS, INC.

25 N 38TH STREET, 11TH FLOOR

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Century Therapeutics, Inc. [ IPSC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		A(1)		475,000	A	$0	3,797,990	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$1.84	02/02/2026		A		945,000		(2)	02/02/2036	Common Stock	945,000	$0	945,000	D

Explanation of Responses:

1. Reflects the grant of restricted stock units ("RSUs"). Each RSU represents a contingent right to receive one share of Issuer common stock. The RSUs vest 25% on February 2, 2027, with the remaining 75% vesting on a quarterly basis for the three years thereafter, in each case subject the Reporting Person's continued service through the applicable vesting date. The RSUs will be settled on each applicable vesting date in shares of the Issuer's common stock.

2. The option vests 25% on February 2, 2027, with the remaining 75% vesting in 36 equal monthly installments, subject to the Reporting Person's continued service through each applicable vesting date.

	/s/ Douglas Carr, Attorney-in-Fact	02/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What equity awards did Century Therapeutics (IPSC) CEO Brent Pfeiffenberger receive?

Brent Pfeiffenberger received 475,000 restricted stock units and a stock option for 945,000 shares. The RSUs were granted at $0 per share, and the option has a $1.84 exercise price, both structured as long-term incentive compensation.

When do Brent Pfeiffenberger’s new RSUs at Century Therapeutics (IPSC) vest?

The RSUs vest 25% on February 2, 2027, with 75% vesting quarterly thereafter. That remaining portion vests over the following three years, contingent on Pfeiffenberger’s continued service with Century Therapeutics through each applicable vesting date.

What are the vesting terms of Brent Pfeiffenberger’s new stock option at IPSC?

The option vests 25% on February 2, 2027, and 75% in 36 monthly installments. All vesting requires Pfeiffenberger’s continued service, and the option covers 945,000 shares of common stock at a $1.84 exercise price, expiring on February 2, 2036.

How many Century Therapeutics (IPSC) shares does Brent Pfeiffenberger hold after this Form 4?

Following the RSU grant, Pfeiffenberger beneficially owns 3,797,990 shares of common stock directly. He also holds 945,000 stock options, giving him additional contingent rights to acquire shares under the specified exercise and vesting conditions.

Are Brent Pfeiffenberger’s new Century Therapeutics (IPSC) RSUs settled in stock or cash?

The RSUs will be settled in shares of Century Therapeutics common stock. Settlement occurs on each vesting date as units vest, assuming Pfeiffenberger continues to provide service through those specified vesting dates described in the award terms.

What is the expiration date of Brent Pfeiffenberger’s new stock option at Century Therapeutics (IPSC)?

The stock option granted to Pfeiffenberger expires on February 2, 2036. Until that date, he may exercise vested portions of the 945,000-share option at the fixed $1.84 exercise price, subject to the vesting schedule and continued service requirement.